Skip to content

Study · Not a test of the peptide alone · 1999

4 results

Atypical endometrial hyperplasia treatment with progestogens and gonadotropin-releasing hormone analogues: long-term follow-up.

Pérez-Medina T, Bajo J, Folgueira G, Haya J, Ortega P

Gynecologic oncology1 May 1999Cited by 29 (Europe PMC)

PMID10329050 (opens in a new tab)DOI10.1006/gyno.1998.5322 (opens in a new tab)PepBankPUB-10329050
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone4

In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  1. 01HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    In atypical endometrial hyperplasia patients, norethisterone acetate plus triptorelin was followed by regression in 84.2% at 5 years.

    In plain wordsIn atypical endometrial hyperplasia patients, norethisterone acetate plus triptorelin was followed by regression in 84.2% at 5 years.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableHyperplasia regression
    Study

    n = 19

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Measurements

    Regression
    84.2%
    5-year follow-up
    Regression
    16 patients
    5-year follow-up

    Source sentences

    Summary
    At a 5-year follow-up, regression was noted in 16 patients (84.2%), persistence in 1 (5.1%), recurrence in 1 (5.1%), and progression in 1 (5.1%).
    3 context sentences
    Summary · context
    After informed consent, they were treated with 500 mg norethisterone acetate weekly for 3 months and 3.75 mg Triptorelin depot every month for 6 months.
    Summary · context
    Three patients failed to complete the study, so the group finally consisted of 19 subjects.
    Summary · context
    They were prospectively followed for 5 years by hysteroscopy and multiple selected biopsies every 6 months.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  2. 02HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    After norethisterone acetate plus triptorelin, atypical endometrial hyperplasia persisted in 1 patient at 5 years.

    In plain wordsAfter norethisterone acetate plus triptorelin, atypical endometrial hyperplasia persisted in 1 patient at 5 years.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableHyperplasia persistence
    Study

    n = 19

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Measurements

    Persistence
    5.1%
    5-year follow-up
    Persistence
    1 patients
    5-year follow-up

    Source sentences

    Summary
    At a 5-year follow-up, regression was noted in 16 patients (84.2%), persistence in 1 (5.1%), recurrence in 1 (5.1%), and progression in 1 (5.1%).
    3 context sentences
    Summary · context
    After informed consent, they were treated with 500 mg norethisterone acetate weekly for 3 months and 3.75 mg Triptorelin depot every month for 6 months.
    Summary · context
    Three patients failed to complete the study, so the group finally consisted of 19 subjects.
    Summary · context
    They were prospectively followed for 5 years by hysteroscopy and multiple selected biopsies every 6 months.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  3. 03HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    After norethisterone acetate plus triptorelin, atypical endometrial hyperplasia recurred in 1 patient at 5 years.

    In plain wordsAfter norethisterone acetate plus triptorelin, atypical endometrial hyperplasia recurred in 1 patient at 5 years.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableHyperplasia recurrence
    Study

    n = 19

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Measurements

    Recurrence
    5.1%
    5-year follow-up
    Recurrence
    1 patients
    5-year follow-up

    Source sentences

    Summary
    At a 5-year follow-up, regression was noted in 16 patients (84.2%), persistence in 1 (5.1%), recurrence in 1 (5.1%), and progression in 1 (5.1%).
    3 context sentences
    Summary · context
    After informed consent, they were treated with 500 mg norethisterone acetate weekly for 3 months and 3.75 mg Triptorelin depot every month for 6 months.
    Summary · context
    Three patients failed to complete the study, so the group finally consisted of 19 subjects.
    Summary · context
    They were prospectively followed for 5 years by hysteroscopy and multiple selected biopsies every 6 months.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

  4. 04HumanNot a test of Triptorelin (Trelstar, Decapeptyl) aloneNon-randomized trialEfficacy outcome

    After norethisterone acetate plus triptorelin, atypical endometrial hyperplasia progressed in 1 patient at 5 years.

    In plain wordsAfter norethisterone acetate plus triptorelin, atypical endometrial hyperplasia progressed in 1 patient at 5 years.

    Peptide
    Triptorelin (Trelstar, Decapeptyl)
    Outcome
    Not applicableHyperplasia progression
    Study

    n = 19

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health

    Measurements

    Progression
    5.1%
    5-year follow-up
    Progression
    1 patients
    5-year follow-up

    Source sentences

    Summary
    At a 5-year follow-up, regression was noted in 16 patients (84.2%), persistence in 1 (5.1%), recurrence in 1 (5.1%), and progression in 1 (5.1%).
    3 context sentences
    Summary · context
    After informed consent, they were treated with 500 mg norethisterone acetate weekly for 3 months and 3.75 mg Triptorelin depot every month for 6 months.
    Summary · context
    Three patients failed to complete the study, so the group finally consisted of 19 subjects.
    Summary · context
    They were prospectively followed for 5 years by hysteroscopy and multiple selected biopsies every 6 months.

    In this study, Triptorelin (Trelstar, Decapeptyl) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Triptorelin (Trelstar, Decapeptyl).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.